MRC Centre for Neuromuscular Diseases 1st (1st December 2010), and 2nd (2nd May 2012) myotonic dystrophy workshops, London, UK and the myotonic dystrophy standards of care and national registry meeting, Newcastle, UK July 2011

Neuromuscular Disorders

Volumn 23, Issue 12, 2013, Pages 1069-1080

  Turner, C ^a   Hilton Jones, D ^b   Lochmuller H ^c   Hanna, M G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CAG 25; CIPROFLOXACIN; COLESTYRAMINE; CREATININE; MEXILETINE; MODAFINIL; PRASTERONE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RECOMBINANT SOMATOMEDIN C; UNCLASSIFIED DRUG;

ACHIEVEMENT; ARTICLE; ARTIFICIAL HEART PACEMAKER; COGNITIVE DEFECT; COMMUNITY CARE; DATA BASE; DAYTIME SOMNOLENCE; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE REGISTRY; DNA STRUCTURE; DRUG DETERMINATION; DRUG DOSE INCREASE; DRUG TARGETING; GENE TARGETING; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HEART DEATH; HEART DISEASE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MEDICAL INFORMATION; MEDICAL RESEARCH; MOLECULAR GENETICS; MORNING DOSAGE; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOTONIA; MYOTONIC DYSTROPHY; NEUROMUSCULAR DISEASE; NONHUMAN; NONINVASIVE VENTILATION; PATIENT CARE; PEDIATRICS; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOTHERAPY; PREGNANCY; PRIORITY JOURNAL; RESISTANCE TRAINING; RESPIRATORY FAILURE; SMOOTH MUSCLE; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; WORKSHOP;

HUMANS; LONDON; MYOTONIC DYSTROPHY; NEUROMUSCULAR DISEASES; REGISTRIES; STANDARD OF CARE;

EID: 84888433937     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.07.006     Document Type: Article

References (51)

1. Hilton-Jones D., Miller A., Parton M., Holton J., Sewry C., Hanna M.G. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscular Disord 2010, 20(2):142-147.
2. Harper P.S. Myotonic dystrophy 2001, Saunders, London. 3rd ed.
3. Mathieu J., Allard P., Potvin L., et al. 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology 1999, 52:1658-1662.
4. Hanostia P., Frenz D. Hypersomonia associated with alveolar hypoventilation in myotonic dystrophy. Neurology 1981, 31:1336-1337.
5. Rubinsztein J.S., Rubinsztein D.C., Goodburn S., et al. Apathy and hypersomnia are common features of myotonic dystrophy. J Neurol Neurosurg Psychiatry 1998, 64:510-515.
6. Ono S., Takahashi K., Jinnai K., et al. Loss of serotonin-containing neurons in the raphe of patients with myotonic dystrophy: a quantitative immunohistochemical study and relation to hypersomnia. Neurology 1998, 50:535-538.
7. Gibbs J.W., Ciafaloni E., Radtke R.A. Excessive daytime somnolence and increased rapid eye movement pressure in myotonic dystrophy. Sleep 2002, 25:672-675.
8. Damian M.S., Gerlach A., Schmidt F., et al. Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology 2001, 56:794-796.
9. MacDonald J.R., Hill J.D., Tarnopolsky M.A. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 2002, 59:180-187.
10. Talbot K., Stradling J., Crosby J., et al. Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy. Neuromuscular Disord 2003, 13:357-364.
11. Assessment report for modafinil containing medicinal products. European Medicines Agnecy. Procedure number: EMEA/H/A-31/1186. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Modafinil_31/WC500105597.pdf.
12. Groh W.J., Groh M.R., Saha C., et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008, 358:2688-2697.
13. Wahbi K., Meune C., Porcher R., et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA 2012, 307(12):1292-1301.
14. Ward A.J. Rimer, M, Killian JM, Dowling, J, Cooper, TA. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet 2010, 19(18):3614-3622.
15. Lee K.S., Cao Y., Witwicka H.E., Tom S., Tapscott S.J., Wang E.H. RNA-binding Protein Muscleblind-like 3 (MBNL3) Disrupts Myocyte Enhancer Factor 2 (Mef2) β-Exon Splicing. J Biol Chem 2010, 285(44):33779-33787.
16. Kimura T., Lueck J.D., Harvey P.J., et al. Alternative splicing of RyR1 alters the efficacy of skeletal EC coupling. Cell Calcium 2009, 45:264-274.
17. Pénisson-Besnier I., Devillers M., Porcher R., et al. Dehydroepiandrosterone for myotonic dystrophy type 1. Neurology 2008, 71(6):407-412.
18. Heatwole C.R., Eichinger K.J., Friedman D.I., et al. Open-Label Trial of Recombinant Human Insulin-like Growth Factor 1/Recombinant Human Insulin-like Growth Factor Binding Protein 3 in Myotonic Dystrophy Type 1. Arch Neurol 2011, 68(1):37-44.
19. Walter M.C. Reilich P, Lochmuller H, et al. Creatine monohydrate in myotonic dystrophy:a double-blind, placebo-controlled clinical study. J Neurol 2002, 249:1717-1722.
20. Tarnopolsky M., Mahoney D., Thompson T., et al. Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1. Muscle Nerve 2004, 29:51-58.
21. Lindeman E., Leffers P., Spaans F., et al. Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: a randomized clinical trial. Arch Phys Med Rehabil 1995, 76(7):612-620.
22. Trip J., Drost G.G., van Engelen B.G.M., et al. Drug treatment for myotonia. Cochrane Database Syst Rev 2007, 4:CD004762.
23. Logigian E.L., Martens W.B., Moxley R.T., et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010, 74(18):1441-1448.
24. Orndahl G., Kock N.G., Sundin T. Smooth muscle activity in myotonic dystrophy. Brain 1973, 96(4):857-860.
25. Adie W.J., Greenfield J.G. Dystrophia myotonica (myotonia atrophica). Brain 1923, 46:73-127.
26. Maas O, Paterson AS. Mental changes in families affected by dystrophia myotonica. Lancet 1937:21-3.
27. Gaul C., Schmidt T., Windisch G., et al. Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2). Neurology 2006, 67:350-352.
28. Modoni A., Silvestri G., Pomponi M.G., Mangiola F., Tonali P.A., Marra C. Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol 2004, 61:1943-1947.
29. Sansone V., Gandossini S., Cotelli M., Calabria M., Zanetti O., Meola G. Cognitive impairment in adult myotonic dystrophies: a longitudinal study. Neurol Sci 2007, 28:9-15.
30. Sistiaga A., Urreta I., Jodar A.M., et al. Cognitive/personality pattern and triplet expansion size in adult myotonic dystrophy type 1 (DM1): CTG repeats, cognition and personality in DM1Psychological. Medicine 2010, 40:487-495.
31. Winblad S., Hellström P., Lindberg C., Hansen S. Facial emotion recognition in myotonic dystrophy type 1 correlates with CTG repeat expansion. J Neurol Neurosurg Psychiatry 2006, 77:219-223.
32. Turnpenny P., Clark C., Kelly K. Intelligence quotient profile in myotonic dystrophy, intergenerational deficit, and correlation with CTG amplification. J Med Genet 1994, 31(4):300-305.
33. Winblad S., Lindberg C., Hansen S. Temperament and character in patients with classical myotonic dystrophy type 1 (DM-1). Neuromuscular Disord 2005, 15:287-292.
34. Weber Y.G., Roebling R., Kassubek J., et al. Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2. Neurology 2010, 74(14):1108-1117.
35. Sergeant N., Sablonnière B., Schraen-Maschke S., et al. Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet 2001, 10(19):2143-2155.
36. Maurage C.A., Udd B., Ruchoux M.M., et al. Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease. Neurology 2005, 65(10):1636-1638.
37. Seznec H., Agbulut O., Sergeant N., et al. Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities. Hum Mol Genet 2001, 10(23):2717-2726.
38. Rönnblom A., Forsberg H., Danielsson A. Gastrointestinal symptoms in myotonic dystrophy. Scand J Gastro 1996, 31(7):654-657.
39. Ronnblom A., Andersson S., Hellstrom P.M., Danielsson A. Gastric emptying in myotonic dystrophy. Eur J Clin Invest 2002, 32:570-574.
40. Ronnblom A., Andersson S., Danielsson A. Mechanisms of diarrhoea in myotonic dystrophy. Eur J Gastroenterol Hepatol 1998, 10:607-610.
41. Monckton D.G., Wong L.J., Ashizawa T., Caskey C.T. Somatic mosaicism, germline expansions, germline reversions and intergenerational reductions in myotonic dystrophy males: small pool PCR analyses. Hum Mol Genet 1995, 4:1-8.
42. Gomes-Pereira M., Monckton D.G. Chemical modifiers of unstable expanded simple sequence repeats: What goes up, could come down. Mutat Res 2006, 598:15-34.
43. Morales F., Couto J.M., Higham C.F., et al. Somatic instability of the expanded CTG triplet repeat in myotonic dystrophy type 1 is a heritable quantitative trait and modifier of disease severity. Hum Mol Genet 2012, 21(16):3558-3567.
44. Warf M.B., Nakamori M., Matthys C.M., Thornton C.A., Berglund J.A. Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci USA 2009, 106(44):18551-18556.
45. Mulders S.A., van den Broek W.J., Wheeler T.M., et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci USA 2009, 106(33):13915-13920.
46. Wheeler T.M., Sobczak K., Lueck J.D., et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009, 325(5938):336-339.
47. Wheeler T.M., Leger A.J., Pandey S.K., et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 2012, 488(7409):111-115.
48. Wang G.-S., Kuyumcu-Martinez M.N., Sarma S., et al. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest 2009, 119(12):3797-3806.
49. Machuca-Tzili L.E., Buxton S., Thorpe A., et al. Zebrafish deficient for Muscleblind-like 2 exhibit features of myotonic dystrophy. Dis Model Mech 2011, 4(3):381-392.
50. Thompson R., Schoser B., Monckton D.G., Blonsky K., Lochmüller H. Workshop report patient registries and trial readiness in myotonic dystrophy-TREAT-NMD/marigold international workshop report. Neuromuscular Disord 2009, 19:860-866.
51. Gagnon C., Chouinard M.C., Laberge L., et al. The DMI expert panel. Health supervision and anticipatory guidance in adult myotonic dystrophy type 1. Neuromuscular Disord 2010, 20:847-851.